Administration of valproic acid improves the survival of patients with glioma treated with postoperative radiotherapy

Oncology Research and Treatment

Wang G. · Guan S. · Yang X. · Sun S. · Huang B. · Li X.

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details Abstract

Objective The aim of this study was to investigate the impact of valproic acid(VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy. Methods We obtained the case data with brain glioma who underwent postoperative radiotherapy from 2012 January to 2019 December. This cohort was heterogeneous. We conducted single factor analysis and multiple factors analysis of the basic features, pathological classification, therapies of all 185 patients using Kaplan-Meier survival curve, log-rank survival significance test and Cox-regression analysis model. Results By the end of the last follow-up, 94 patients had died and 96 had recurred in all 185 cases.The median follow-up time of this study was 47 months.The median overall survival (OS) and progression-free survival (PFS) times were 34 and 27 months, respectively. The 1-, 3- and 5-year OS rates were 86.49%, 48.11%, and 14.60%, respectively. The 1-, 3- and 5-year progression-free survival rates were 80.00%, 43.78%, and 12.97%, respectively. Univariate analysis revealed that age, pathological grade, and VPA administration were all associated with patients’ prognosis (p

S. Karger AG, Basel

Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif